Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD
Key outcomes included major adverse cardiovascular events (MACE), venous thromboembolism (VTE), kidney disease progression, and all-cause mortality, an outcome spectrum highly relevant to patients with SLE and T2D
Serious side effects and warnings Trulicity carries a Boxed Warning for thyroid C-cell tumors in rats, but it is unknown whether Trulicity would cause this type of cancer in humans
Vora B, Wen A, Yee SW, et al
Pharmacies ran dry
More importantly, platelets can release a potent, long-term anti-inflammatory protein called IL-1 RA
